CYP3A5*3 polymorphism and cancer risk: A meta-analysis and meta-regression

Tumor Biology

Volumn 34, Issue 4, 2013, Pages 2357-2366

  Wang, Bao Sheng ^a   Liu, Zhen ^a   Xu, Wei Xue ^a   Sun, Shao Long ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; CYP3A5; Meta analysis; Meta regression; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 3A5; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ACUTE LEUKEMIA; AFRICA; ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CHRONIC LEUKEMIA; COLORECTAL CANCER; CYP3A5 GENE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LIVER CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; LEUKEMIA; LIVER TUMOR; MALE; META ANALYSIS; NEGRO; NEOPLASM; PROSTATE TUMOR; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA; LIVER NEOPLASMS; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK;

EID: 84881475524     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0783-2     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Are C, Rajaram S, Are M, Raj H, Anderson BO, Chaluvarya Swamy R, et al. A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol. 2013;107:221-6.
3. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni Jr JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta. 2001;1471:C1-10.
4. Fontham ET, Thun MJ, Ward E, Portier KM, Balch AJ, Delancey JO, et al. American Cancer Society perspectives on environmental factors and cancer. CA Cancer J Clin. 2009;59:343-51.
5. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177-83.
6. Futreal PA, Kasprzyk A, Birney E, Mullikin JC, Wooster R, Stratton MR. Cancer and genomics. Nature. 2001;409:850-2.
7. Bartsch H, Dally H, Popanda O, Risch A, Schmezer P. Genetic risk profiles for cancer susceptibility and therapy response. Recent Results in Cancer Research Fortschritte der Krebsforschung Progres dans les Recherches sur le. Cancer. 2007;174:19-36.
8. Nebert DW, Dalton TP. The role of cytochrome p450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947-60.
9. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001;11:111-21.
10. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 2003;13:461-72.
11. Agundez JA. Cytochrome p450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211-24.
12. Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 2005;225:275-82.
13. Li ZH, Tsuchiya N, Narita S, Inoue T, Horikawa Y, Kakinuma H, et al. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population. Cancer Lett. 2005;225:237-43.
14. Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer J Int Cancer. 2008;122:2511-6.
15. Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev: APJCP. 2010;11:781-4.
16. Bethke L, Webb E, Sellick G, Rudd M, Penegar S, Withey L, et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer. 2007;7:123.
17. Gervasini G, Garcia-Martin E, Ladero JM, Pizarro R, Sastre J, Martinez C, et al. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007;7:118.
18. Petrova DT, Yaramov N, Toshev S, Nedeva P, Maslyankov S, von Ahsen N, et al. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie. 2007;30:559-63.
19. Bajpai P, Tripathi AK, Agrawal D. Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients. Mol Cell Biochem. 2010;336:49-54.
20. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, et al. Strengthening the reporting of observational studies in epidemiology-molecular epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med. 2011;8:e1001117.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-58.
22. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123-37.
23. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336:1413-5.
24. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676-80.
25. Huang Z, Cai YH, Chen JN, He HL, Li J, Lu J. Association between CYP3A5 gene polymorphisms and childhood acute leukemia. Chin J Pediatr. 2007;45:546-8.
26. Lu HX, Feng ZB, Feng XL. A case-control study on the association of hepatocellular carcinoma with genetic polymorphisms of CYP3A5 in a highly aflatoxin b1 contaminated guangxi area. Chin J Hepatol. 2007;15:705-6.
27. Azarpira N, Ashraf MJ, Khademi B, Darai M, Hakimzadeh A, Abedi E. Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol Biol Rep. 2011;38:5443-8.
28. Borst L, Wallerek S, Dalhoff K, Rasmussen KK, Wesenberg F, Wehner PS, et al. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol. 2011;86:477-83.
29. Kristiansen W, Haugen TB, Witczak O, Andersen JM, Fossa SD, Aschim EL. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility. Int J Androl. 2011;34:77-83.
30. Lim JS, Chen XA, Singh O, Yap YS, Ng RC, Wong NS, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71:737-50.
31. Rao DN, Manjula G, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. Association of CYP3A5*3 polymorphism with development of acute leukemia. Indian J Hum Genet. 2011;17:175-8.
32. Fernandez P, Zeigler-Johnson CM, Spangler E, van der Merwe A, Jalloh M, Gueye SM, et al. Androgen metabolism gene polymorphisms, associations with prostate cancer risk and pathological characteristics: a comparative analysis between south African and Senegalese men. Prostate Cancer. 2012;2012:798634.
33. Silveira VS, Canalle R, Scrideli CA, Queiroz RG, Lopes LF, Tone LG. CYP3A5 and NAT2 gene polymorphisms: role in childhood acute lymphoblastic leukemia risk and treatment outcome. Mol Cell Biochem. 2012;364:217-23.
34. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009;10:1017-24.
35. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-94.
36. Roco A, Quinones L, Agundez JA, Garcia-Martin E, Squicciarini V, Miranda C, et al. Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations. Front Genet. 2012;3:229.
37. Rosenthal R, DiMatteo MR. Meta-analysis: recent developments in quantitative methods for literature reviews. Annu Rev Psychol. 2001;52:59-82.
38. Rendic S, Guengerich FP. Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol. 2012;25:1316-83.
39. Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, et al. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos: Biol Fate Chem. 2012;40:1686-97.
40. Ioannidis JP, Lau J. Pooling research results: benefits and limitations of meta-analysis. Jt Comm J Qual Improv. 1999;25:462-9.